Medicare Enrolled

Dr. Abbas Mehdi, M.D.

Neurology · Fresno, CA
Practice pattern: Mixed Practice — Diverse clinical practice across multiple procedure types
Speaking/Promotional
7585 N CEDAR AVE, Fresno, CA 93720
5592431232
In practice since 2005 (20 years)
NPI: 1356348387 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Mehdi from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Mehdi? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Mehdi

Dr. Abbas Mehdi is a neurology specialist in Fresno, CA, with 20 years of NPI registration. Based on federal Medicare data, Dr. Mehdi performed 16,612 Medicare services across 1,060 unique beneficiaries.

Between the years covered by Open Payments, Dr. Mehdi received a total of $28,745 from 59 pharmaceutical and/or device companies across 423 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in neurology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Mehdi is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 20 years in practice ▲ Top 6% volume in CA $28,745 industry payments

Medicare Practice Summary

Medicare Utilization ↗
16,612
Medicare services
Top 6% in CA for neurology
1,060
Unique beneficiaries
$43
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~831 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Immune globulin infusion (Gammagard)
An injection of immune globulin (Gammagard Liquid) to provide antibodies. The dose specified is 500 mg.
14,970 $36 $60
Additional hour of intravenous infusion
This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis.
345 $17 $160
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
178 $85 $175
Neurobehavioral status exam, first hour
A clinical assessment of neurobehavioral status lasting one hour. This evaluation examines mental and behavioral functions.
166 $71 $150
Psychological test administration, first 30 minutes
A technician administers psychological or neuropsychological testing for the first 30 minutes.
166 $27 $150
EEG, extended monitoring
A test that records electrical activity in the brain while the patient is both awake and asleep.
132 $370 $550
Nerve conduction studies, 11-12
A diagnostic test that measures how well nerves send electrical signals. It involves performing 11 to 12 separate nerve conduction studies.
129 $198 $500
Intravenous infusion, 1 hour or less
Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less.
129 $52 $400
Office visit, established patient, complex (40-54 min)
An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter.
122 $135 $225
Awake and drowsy EEG
A test that records electrical activity in the brain while the patient is awake and drowsy.
99 $310 $550
Electromyography of arm or leg muscles
A test that measures the electrical activity in the muscles of the arm or leg using a needle electrode. It helps evaluate the health of muscles and the nerve cells that control them.
97 $80 $148
New patient office visit (45-59 min)
An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter.
46 $120 $330
New patient office visit, complex (60-74 min) 33 $169 $450
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
93.0% high complexity
1.4% medium
5.6% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$28,745
Total received (2018-2024)
Avg $4,106/year across 7 years
Top 12% in CA for neurology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
59
Companies
423
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$20,177 (70.2%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$8,567 (29.8%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$2,065
2023
$1,733
2022
$1,523
2021
$1,328
2020
$1,109
2019
$9,753
2018
$11,234

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
ABBVIE INC.
$251
Celgene Corporation
$224
Genentech USA, Inc.
$172
EMD Serono, Inc.
$167
SK Life Science, Inc.
$163
ARGENX US, INC.
$156
Novartis Pharmaceuticals Corporation
$147
Alexion Pharmaceuticals, Inc.
$147
Neurelis, Inc.
$103
Takeda Pharmaceuticals U.S.A., Inc.
$76
NEUROPACE, INC.
$68
Amgen Inc.
$61
Grifols USA, LLC
$51
Otsuka Pharmaceutical Development & Commercialization, Inc.
$42
UCB, Inc.
$33
Otsuka America Pharmaceutical, Inc.
$26
Eisai Inc.
$24
Lilly USA, LLC
$24
Sumitomo Pharma America, Inc.
$23
PFIZER INC.
$22
LivaNova USA, Inc.
$19
MDD US Operations, LLC
$17
Octapharma USA, Inc.
$17
Biogen, Inc.
$16
Amneal Pharmaceuticals LLC
$14
Top 3 companies account for 31.3% of 2024 payments
All-time payments by company (2018-2024) ›
EMD Serono, Inc.
$19,432
LivaNova USA, Inc.
$1,866
Novartis Pharmaceuticals Corporation
$805
UCB, Inc.
$518
Genentech USA, Inc.
$502
Celgene Corporation
$455
ARGENX US, INC.
$422
Alexion Pharmaceuticals, Inc.
$389
Biogen, Inc.
$374
Neurelis, Inc.
$368
SK Life Science, Inc.
$317
Teva Pharmaceuticals USA, Inc.
$306
ABBVIE INC.
$303
Lundbeck LLC
$177
Sunovion Pharmaceuticals Inc.
$176
Amgen Inc.
$163
Takeda Pharmaceuticals U.S.A., Inc.
$155
MDD US Operations, LLC
$137
Neurocrine Biosciences, Inc.
$118
AbbVie Inc.
$116
Adamas Pharmaceuticals, Inc.
$116
Lilly USA, LLC
$93
Janssen Pharmaceuticals, Inc
$87
Eisai Inc.
$71
AstraZeneca Pharmaceuticals LP
$69
NEUROPACE, INC.
$68
PFIZER INC.
$66
ACADIA Pharmaceuticals Inc
$56
Biohaven Pharmaceutical Holding Company Ltd.
$52
Grifols USA, LLC
$51
Kyowa Kirin, Inc.
$50
Mallinckrodt Hospital Products Inc.
$49
MITSUBISHI TANABE PHARMA AMERICA, INC.
$49
Esperion Therapeutics, Inc.
$49
Alnylam Pharmaceuticals Inc.
$44
GENZYME CORPORATION
$43
Nevro Corp.
$43
Otsuka Pharmaceutical Development & Commercialization, Inc.
$42
Banner Life Sciences, LLC
$40
Allergan, Inc.
$39
Amneal Pharmaceuticals LLC
$38
BANNER LIFE SCIENCES, LLC
$38
Biohaven Pharmaceuticals, Inc.
$38
EISAI INC.
$36
CATALYST PHARMACEUTICALS, INC.
$35
Otsuka America Pharmaceutical, Inc.
$26
Cala Health, Inc.
$24
TG THERAPEUTICS, INC.
$23
Horizon Therapeutics plc
$23
Mitsubishi Tanabe Pharma America, Inc.
$23
Sumitomo Pharma America, Inc.
$23
Allergan Inc.
$22
US WorldMeds, LLC
$21
InSightec,Inc
$20
Amylyx Pharmaceuticals, Inc.
$17
Octapharma USA, Inc.
$17
Sarepta Therapeutics, Inc.
$17
Xeris Pharmaceuticals, Inc.
$14
ARBOR PHARMACEUTICALS, INC.
$13
Top 3 companies account for 76.9% of all-time payments
Associated products mentioned in payments ›
ACTHAR · ADUHELM · AJOVY · ANDEXXA · APTIOM · AUBAGIO · AUSTEDO · AVONEX · Aimovig · BAFIERTAM · BOTOX · BRILINTA · BRIUMVI · Briviact · CALA TRIO · CREXONT · DUOPA · EMGALITY · EXONDYS 51 · Enspryng · Exablate · FIRDAPSE · Fycompa · GAMMAGARD · GOCOVRI · Gamunex-C · Gocovri · HYQVIA · Horizant · INGREZZA · KESIMPTA · KEVEYIS · KISUNLA · KYNMOBI · Leqembi · MAVENCLAD · MAYZENT · Mavenclad · NEXLIZET · NORTHERA · NOURIANZ · NUPLAZID · NURTEC ODT · OCREVUS · OCTAGAM IMMUNE GLOBULIN (HUMAN) · ONFI · ONPATTRO · Ocrevus · Omnia · Ongentys · PANZYGA · Ponvory · QULIPTA · RADICAVA · RELYVRIO · REXULTI · RNS Neurostimulator Kit · RYTARY · Rebif · SKYCLARYS · SOLIRIS · Senza · Soliris · TECFIDERA · TYSABRI · UBRELVY · ULTOMIRIS · UPLIZNA · VALTOCO · VNS - Sentiva · VNS THERAPY SENTIVA MODEL 1000 GENERATOR · VNS Therapy · VUMERITY · VYEPTI · VYVGART · VYVGART HYTRULO · Vimpat · XCOPRI · Xadago · ZEPOSIA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (70%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in neurology and does not inherently indicate bias, but patients may wish to be aware.

Looking for a neurology specialist in Fresno?
Compare neurologists in the Fresno area by procedure volume, costs, and industry payment transparency.
Browse neurologists nearby

Geographic Context

Neurologists within 10 mi
33
Per 100K population
3.3
County median income
$71,434
Nearest hospital
SAINT AGNES MEDICAL CENTER
0.0 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Mehdi is a mixed practice specialist, with above-average Medicare volume (top 6% in CA), with speaking/promotional industry engagement in the top 12% of CA peers, with 20 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Mehdi experienced with immune globulin infusion (gammagard)?
Based on Medicare claims data, Dr. Mehdi performed 14,970 immune globulin infusion (gammagard) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Mehdi receive payments from pharmaceutical companies?
Yes. Dr. Mehdi received a total of $28,745 from 59 companies across 423 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Mehdi's costs compare to other neurologists in Fresno?
Dr. Mehdi's average Medicare payment per service is $43. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Mehdi) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →